Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BKM120 + Cetuximab in Recurrent/Metastatic Head and Neck Cancer
NCT01816984Phase 2Completed
- Sponsor
- University of Chicago
- Start
- May 2013
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buparlisib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Chicago. Started May 2013; status: completed.
02
Drugs
buparlisib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01816984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01816984.